N/A N=200 Provision of HIV Self-Test Kit to Emergency Department Patients
HIV Infections
Primary: Number of Participants Who Did HIV Testing — 36; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=250 Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
HIV Infections · Memory
Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…
Phase 4 N=212 Alignment of PrEP Use With HIV Risk in Young Women and Men
Pre-Exposure Prophylaxis · Sexually Transmitted Diseases, Bacterial · HIV Infections
Primary: Visits With PrEP Dispensation to Female Study Participants Reporting Sexual Behaviors or STI Symptoms — 211 Visits
N/A N=500 Expanding HIV Testing Among Uganda Adults Who Utilize Traditional Healers
HIV/AIDS · Health Behaviors
Primary: Number of TH Clients Who Received HIV Testing — 57; 250 Participants — p=<0.001
Phase 4 N=30 An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
HIV-2 Infection
Primary: Death — 0 Participants
N/A N=216 Crowdsourcing to Reduce HIV Stigma Among Adolescents and Young Adults in Kazakhstan
Stigma, Social · HIV Testing
Primary: Mean Score Change in Total HIV Stigma Scale — 47.48; 47.89; 44.60; 47.32 units on a scale — p=0.083
N/A N=151 Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use
HIV Infection
Primary: Baseline HIV DNA Reservoir: Total HIV DNA — 3.83; 3.67; 3.40 Log10 HIV DNA copies/10^6 CD4 T cells — p=0.048
Phase 2 N=15 Enhancement by Poly-ICLC During HIV-1 Infection
HIV-1 Infected Adults With Chronic HIV-1 Infection
Primary: Number Participants With Adverse Events — 11; 3 Participants
N/A N=58 Texting to Improve Adherence in HIV+ With Bipolar Disorder
HIV Disease · Bipolar Disorder
Primary: Proportion Adherent to ARV and Psychotropic Medication by Electronic Monitoring System (MEMS) — 90.3; 90.0; 83.9; 90.0 percentage of taken doses — p=0.95
Phase 1 N=33 Therapeutic Vaccine for HIV
HIV · Therapeutic Vaccine
Primary: The Rate of Related Adverse Events in Subjects Who Began cART During Acute or Early HIV-1 Infection. — 0; 0 Related Adverse Events
N/A N=189 The OPENS Trial: Offering Women PrEP (Aim 1)
Human Immunodeficiency Virus Transmission · Sexually Transmitted Diseases
Primary: PrEP Prescriptions (As Measured by Chart Review) — 1; 0 Participants — p=0.51
Phase 2 N=46 Rifaximin for Chronic Immune Activation in People With HIV
HIV
Primary: Changes in Soluble Cluster of Differentiation 14 (sCD14) Levels Between the Placebo and Rifaximin Phases of the Study — 0.0067; 0.0035 mcg/mL — p=0.51
N/A N=151 Addressing Drug Use Stigma in Human Immunodeficiency Virus (HIV) Care and Treatment Clinics in Tanzania
Drug Use Stigma in HIV Treatment Clinics
Primary: Modified Opening Minds Scale for Health Providers (OMS-HC) — 22.92; 16.82 score on a scale
N/A N=224 Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)
HIV Infections · Syphilis
Primary: Participants Linked Either to Care (PrEP or ART) — 51; 50 Participants
N/A N=300 HIV HOspital TEsting: Bringing the Hidden to Light in the Hospital Setting
Hiv · HIV Infections · AIDS
Primary: Prevalence of HIV Infection — 6 Participants